Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of DNOW Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased DNOW securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Financial Performance and Market Reaction - DNOW shares experienced a significant decline of 19.1% on February 20, 2026, following the release of disappointing fourth-quarter 2025 financial results, which included a substantial loss and missed Wall Street expectations [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Driven Brands Holdings Inc. (NASDAQ: DRVN) between May 9, 2023 and February 24, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2026. SO WHAT: If you purchased Driven Brands common stock during the Cla ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period from February 26, 2025, to December 15, 2025, due to alleged misleading statements and failures to disclose critical information regarding the REZOLVE-AA trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards [5]. - It is alleged that this failure likely had a significant negative impact on the results of the REZOLVE-AA trial, overstating its overall integrity and prospects [5]. - The lawsuit asserts that when the true details became known, investors suffered damages as a result of the misleading public statements [5]. Group 2: Participation Information - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Navan, Inc. (NASDAQ: NAVN) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Offering Documents”) issued in connection with Navan’s October 2025 initial public offering (the “IPO”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court ...

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Navan, Inc. related to its October 2025 IPO, claiming that the Offering Documents were false and misleading [1][5]. Group 1: Lawsuit Details - The class action lawsuit alleges that Navan's Offering Documents omitted critical information regarding increased "sales and marketing" expenses at the time of the IPO, leading to investor damages when the truth was revealed [5]. - Investors who purchased Navan common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to move the Court to serve as lead plaintiff is April 24, 2026 [3][5]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PayPal Holdings, Inc. common stock between February 25, 2025, and February 2, 2026, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought PayPal stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 20, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its number of settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3] Group 3: Case Specifics - The lawsuit alleges that PayPal's management provided overly optimistic statements regarding the company's financial targets and growth potential while concealing material adverse facts about its salesforce capabilities [4] - It is claimed that these misleading statements led to investor damages when the true state of the company was revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2026, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Background - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [4]. - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [4]. - The lawsuit claims that when the true details became known, investors suffered damages [4].

New York, New York--(Newsfile Corp. - March 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Richtech Robotics Inc. (NASDAQ: RR) between January 27, 2026 and 12:00 PM ET on January 29, 2026, both dates inclusive (the "Class Period"), of the important April 3, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased Richtech Robotics securities during the Class Period you may be entitled to compensatio ...

New York, New York--(Newsfile Corp. - March 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lakeland Industries, Inc. (NASDAQ: LAKE) between December 1, 2023 and December 9, 2025, inclusive (the "Class Period"), of the important April 24, 2026 lead plaintiff deadline.SO WHAT: If you purchased Lakeland securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...